No Carolina / NY / Florida
Ph: 561.316.3330

PathogenDx’s New Rapid, Single Test Detects Salmonella and 13 Serotypes in Poultry as Foodborne Illness Remains a Significant Threat to Public Health in the US

Serotypes Responsible for the Vast Majority of All Harmful Salmonella Infections Are Rapidly Identified in One Efficient Test – in One Lab Shift

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • At a time when foodborne illness remains a significant threat to public health in the US, PathogenDx, a leader in next-generation microarray technology for better health and safety, announced the launch of SeroX, a new rapid, single test that detects Salmonella and 13 serotypes in a single shift to support the food industry’s poultry sector.
  • PathogenDx’s SeroX Assays includes the Company’s patented Dynamic Dimensional Detection (“D3 Array™”) technology, which is comprised of up to 108 probes – in triplicate, in a single well – to deliver a new and innovative approach to multiplexed molecular testing.
  • Amplified DNA binding is enabled easily across a flexible, open 3D cross-linked array architecture, which results in a more flexible, faster and lower cost test than qPCR or NGS technology.

At a time when foodborne illness remains a significant threat to public health in the US, PathogenDx, a leader in next-generation microarray technology for better health and safety, announced the launch of SeroX, a new rapid, single test that detects Salmonella and 13 serotypes in a single shift to support the food industry’s poultry sector.

“Salmonella outbreaks are a huge issue facing poultry producers, particularly when you look at the astronomical risk and costs associated with an outbreak,” said PathogenDx Co-founder and CEO Milan Patel. “For every confirmed case of Salmonella, another 30 go undetected. In fact, the Centers for Disease Control and Prevention (“CDC”) estimates that each year one in six Americans – or 48 million people – get sick, 128,000 are hospitalized and 3,000 die of foodborne diseases. To make matters worse, food contaminated with Salmonella usually looks, tastes and smells normal. That’s why next-gen tests like SeroX are critical to preventing infection and minimizing this threat to public health in the US.”

Patel added,” With SeroX there is no need for qPCR, NGS testing or both. SeroX delivers advanced gene detection of Salmonella and 13 serotypes from primary enrichment, and ensures an easier, simplified workflow and cost savings that poultry producers require to optimize production and food safety. SeroX results are also ready in a single-shift and deliver the lowest cost per sample when compared to sequence and antisera based serotyping methods.”

PathogenDx’s SeroX Assays includes the Company’s patented Dynamic Dimensional Detection (“D3 Array™”) technology, which is comprised of up to 108 probes – in triplicate, in a single well – to deliver a new and innovative approach to multiplexed molecular testing. Amplified DNA binding is enabled easily across a flexible, open 3D cross-linked array architecture, which results in a more flexible, faster and lower cost test than qPCR or NGS technology. Additionally, SeroX rapidly detects the serotypes responsible for the vast majority of all harmful Salmonella infections in one efficient test, including:

Enteritidis
Typhimurium
Newport
Javiana
I 4,[5],12:i:- (Monophasic Typhimurium)
Heidelberg
Muenchen
Saintpaul
Montevideo
Infantis
Braenderup
Oranienberg
Thompson

For more information, visit https://pathogendx.com/food/

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Sphere Fluidics Awarded Gold Accreditation by Investors in People

Dale Levitzke, CEO of Sphere Fluidics, expressed his pride in the achievement: "Receiving the Gold Investors in People Award is a significant milestone for Sphere Fluidics. It recognizes the dedication and hard work of our entire team in creating a workplace where people feel valued, supported, and empowered to reach their full potential. This award is not just a tribute to our HR practices, but a testament to our commitment to nurturing a culture of excellence and continuous improvement."

Jumpcode Genomics and Takara Bio USA Announce Global Patent Partnership

Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, and Takara Bio USA, Inc. (“Takara Bio USA”), a wholly-owned subsidiary of Takara Bio Inc., today announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS...

CERo Therapeutics Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics is continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA

By using this website you agree to accept Medical Device News Magazine Privacy Policy